Skip to main content

GRI Bio, Inc.

GRI
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001824293

No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding GRI Bio, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of GRI: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders813+5
Shares263.6K310.9K+47.3K (+17.9%)
Value$74.0K$88.5K+$14.5K (+19.6%)

New holders (8)

Institutions that held GRI Bio, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to GRI in Q4 2022
InstitutionSharesValue% of portfolio
Two Sigma Investments, LP62,836$18.2K0.00%
Two Sigma Securities, LLC36,604$10.6K0.00%
UBS Group AG20,347$5.90K0.00%
Cetera Advisor Networks LLC11,711$3.40K0.00%
Commonwealth Equity Services, LLC10,350$3.00K0.00%
Millennium Management LLC10,274$3.00K0.00%
Archer Investment Corp100$290.00%
Morgan Stanley90$260.00%

Sold out (3)

Institutions that held GRI Bio, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of GRI in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Susquehanna International Group, LLP48,644$14.0K
Vanguard Group Inc22,146$6.00K
FMR LLC10,000$3.00K